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BaCKgRoUND aND aIMS: NAFLD is a growing pub-
lic health burden. However, the pathogenesis of NAFLD has 
not yet been fully elucidated, and the importance of genetic 
factors has only recently been appreciated. Genomic studies 
have revealed a strong association between NAFLD progres-
sion and the I148M variant in patatin- like phospholipase 
domain- containing protein 3 (PNPLA3). Nonetheless, very 
little is known about the mechanisms by which this gene and 
its variants can influence disease development. To investigate 
these mechanisms, we have developed an in vitro model that 
takes advantage of the unique properties of human- induced 
pluripotent stem cells (hiPSCs) and the CRISPR/CAS9 gene 
editing technology.
appRoaCH aND ReSUltS: We used isogenic hiPSC 
lines with either a knockout (PNPLA3KO) of the PNPLA3 
gene or with the I148M variant (PNPLA3I148M) to model 
PNPLA3- associated NAFLD. The resulting hiPSCs were dif-
ferentiated into hepatocytes, treated with either unsaturated 
or saturated free fatty acids to induce NAFLD- like pheno-
types, and characterized by various functional, transcriptomic, 
and lipidomic assays. PNPLA3KO hepatocytes showed higher 
lipid accumulation as well as an altered pattern of response 
to lipid- induced stress. Interestingly, loss of PNPLA3 also 
caused a reduction in xenobiotic metabolism and predisposed 
PNPLA3KO cells to be more susceptible to ethanol- induced 
and methotrexate- induced toxicity. The PNPLA3I148M cells 
exhibited an intermediate phenotype between the wild- type 
and PNPLA3KO cells.
CoNClUSIoNS: Together, these results indicate that 
the I148M variant induces a loss of function predispos-
ing to steatosis and increased susceptibility to hepatotoxins. 
(Hepatology 2021;0:1-20).
NAFLD is now the leading cause of chronic liver disease in the developed world.(1) NAFLD is defined by accumulation of fat within the liver, 
which ranges from simple steatosis to NASH, cirrho-
sis, and HCC. With approximately one in four adults 
suffering from some form of the disease, it represents 
a growing cause of liver- related morbidity and mortal-
ity.(2) Despite this growing public health burden, the full 
pathophysiology of NAFLD remains unclear.
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Until recently, NAFLD was considered to be a con-
sequence of metabolic syndrome; however, recent stud-
ies suggest that genetic factors influence disease onset 
and progression.(3) Genome- wide association studies 
identified the I148M variant of patatin- like phos-
pholipase domain- containing protein 3 (PNPLA3) 
to be associated with the development and progres-
sion of NAFLD, regardless of underlying metabolic 
disease.(4,5) Since this variant was identified, clinical 
studies have confirmed the association of this variant 
with the full spectrum of the disease.(6,7) Studies have 
shown that this protein could have triglyceride lipase, 
acyl transferase, and retinyl palmitate hydrolase activ-
ity.(8- 10) However, the function of PNPLA3 has yet 
to be fully elucidated. Accordingly, it remains unclear 
whether the I148M variant is a loss or gain of func-
tion variant. In vitro studies showed that the I148M 
variant restricts access of the substrate to the active 
site of the enzyme and results in a profound loss of 
lipase activity indicating a possible loss of function.(11) 
However, when the PNPLA3 protein was knocked 
out in mice, no phenotype was observed.(12)
This lack of information regarding the functions 
and disease associations of PNPLA3 could also be 
explained by species divergence between human and 
mouse. Indeed, these animal models display two 
major differences: (1) the mouse and human proteins 
only share approximately 58% homology, and (2) the 
mouse protein is highly expressed in adipose tissue 
while the human protein is expressed 10 times higher 
in the liver.(9,13,14) Furthermore, when the human 
PNPLA3 protein is overexpressed in mouse livers, it 
cannot be nutritionally regulated, indicating that the 
protein may have distinct functions in each species.(14)
For these reasons, we have chosen to develop an 
in vitro human model of PNPLA3- induced NAFLD. 
We used CRISPR/CAS9 to generate hiPSC lines with 
either a complete knockout (KO) of the PNPLA3 gene 
(PNPLA3KO) or with the I148M variant knocked in 
(PNPLA3I148M). The hiPSC lines were then differen-
tiated into hepatocyte- like cells (HLCs) and treated 
with either oleic acid (OA) or palmitic acid (PA) to 
induce steatosis and lipotoxicity, respectively. Our data 
suggest that lack of PNPLA3 expression impairs lipid 
metabolism, contributing to increased steatosis. The 
I148M variant was also determined to be a loss of 
function variant, because PNPLA3I148M cells behaved 
quite similarly to PNPLA3KO cells. Loss of PNPLA3 
functionality resulted in global metabolic dysfunction, 
leading to increased steatosis and reduced xenobiotic 
metabolism, which makes cells more susceptible to 
other forms of hepatotoxicity.
Experimental Procedures
HIpSC CUltURe
The hiPSC lines, FSPS13B(15) and A1ATDR/R,(16) 
were obtained from the hiPSC Core Facility, 
Cambridge Biomedical Research Center. The cells 
were maintained on vitronectin- coated plates in 
Essential 8 medium at 37°C and 5% CO2 and split 
every 5- 7 days using 0.5 mM EDTA.
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CRISpR/CaS9 taRgetINg
The single- guide RNA (sgRNA) sequences were 
designed to target exon 3. The sgRNA was cloned 
into the pX459 expression vector and nucleofected 
into hiPSCs using the Lonza nucleofection kit. 
Selection was performed for 48 hours using 1 µg/mL 
of Puromycin. DNA from selected clonal colonies was 
extracted, amplified, and purified before sequencing. 
The sequences for the sgRNA, single- stranded donor 
oligonucleotides (ssODNs), and genotyping primers 
can be found in Supporting Table S1.
DIFFeReNtIatIoN pRotoCol
The differentiation protocol to generate HLCs from 
hiPSCs was adapted from Hannan et.al.(17) hiPSCs 
were split into single- cell suspension and seeded at a 
concentration of 50,000 cells/cm2 on gelatin- coated 
plates. Cells were allowed to recover for 48  hours 
before beginning the differentiation. Throughout dif-
ferentiation, cells were cultured at 37˚C, 5% CO2, and 
5% O2. A full description of HLC generation and a 
list of media and supplementation components can be 
found in Supporting Table S2.
3D Cell CUltURe aND lIpID 
tReatMeNt
For 3D culture experiments, HLCs were dis-
sociated into small clumps with Cell Dissociation 
Buffer (ThermoFisher Scientific, Waltham, MA) at 
day 23 of differentiation. Cell count was estimated 
using the Luna Automated Cell Counter (Logos 
Biosystems, Annandale, VA). Cells were then resus-
pended at 2.0  ×  106 cells/mL in Growth Factor 
Reduced Matrigel (Corning, Corning, NY). The 
Matrigel was dispersed in 24- well plates at 50  µL/
well, and the plates were stored upside- down at 
37ºC until the Matrigel had completely solidified. 
The Matrigel was then overlaid for 24  hours with 
3D culture medium supplemented with 20  ng/mL 
oncostatin M, and 50 ng/mL HGF.
OA, PA, and stearic acid (SA) were reconstituted 
to 100  mM in 95% ethanol. A total of 250  µM of 
each fatty acid was conjugated to 12.5% bovine serum 
albumin (60ºC for 10  minutes) to facilitate uptake 
into the cells. The cells were maintained in their 
respective medium for 7 days at 37ºC, 5% CO2, and 
5% O2, with medium changes every 48 hours.
IMMUNoFlUoReSCeNCe 
MICRoSCopy, FloW CytoMetRy, 
QUaNtItatIVe pCR, lIpIDoMICS, 
RNa SeQUeNCINg, aND StatIStICS
See Supporting Materials and Methods for details.
tRIglyCeRIDe BloCKINg aSSay
Triglyceride formation was blocked using 0.5 µM 
Triacsin C or 10 µM T863. See Supporting Materials 
and Methods for details.
toXICIty aSSayS
Toxicity was induced in FFA laden cells by treat-
ing cells with either 100 mM ethanol for 48 hours 
followed by 24 hour treatment with 20 ng/mL TNFa 
or 100µM methotrexate for 7 days. See supporting 
Materials and Methods for details.
CytoCHRoMe p450 aCtIVIty, 
pReSto BlUe VIaBIlIty aSSay, 
CaSpaSe 1 INFlaMMaSoMe aSSay
CYP3A4 activity was measured using the P450- 
Glo CYP3A4 Assay System (Promega, Madison, WI) 
according to the manufacturer’s protocol. Cell viability 
was measured using the Presto Blue Viability Reagent 
(ThermoFisher Scientific, Waltham, MA) Caspase 
1 activation was measured using the Caspase- Glo 1 
Inflammasome Assay System (Promega, Madison, WI). 
See supporting Materials and Methods for details.
QpCR
Total RNA was extracted using the RNEasy Micro 
Kit (Qiagen, Germantown, MD) and reverse transcribed 
using Superscript II Reverse Transcriptase (ThermoFisher 
Scientific, Waltham, MA). The qPCR master mix 
was prepared using Kapa Sybr Fast (Kapa Biosystems, 
Inc., Wilmington, MA). See supporting Materials and 
Methods for primer sequences and further details.
IMMUNoFlUoReSCeNCe 
MICRoSCopy
Cells were fixed using 4% paraformaldehyde and 
stained with the appropriate primary and secondary 
antibodies. See supporting Materials and Methods for 
a detailed protocol and a list of antibodies used.
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FloW CytoMetRy
HLCs grown in 2D were dissocited using TryplE 
Express (ThermoFisher Scientific, Waltham, MA), 
fixed in 4% paraformaldehyde, and stained with 1 
µg Bodipy (ThermoFisher Scientific, Waltham, MA) 
before being analysed by flow cytometry. See support-
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lIpIDoMICS
Cells were removed from Matrigel using Cell 
Recovery Solution (Corning, Corning, NY) and 
the total lipids were extracted using a Folch lipid 
extraction. The lipids were analysed via direct injec-
tion liquid chromatography mass spectromety. 
The lipidomic data was then analyzed using the 
MetaboAnalyst web- based analytical pipeline. See 
supporting Materials and Methods for details.
RNa SeQUeNCINg
Total RNA was extracted using the RNeasy Micro 
Kit and the library preparation was performed using 
the NEBNext Ultra II Directional RNA Library Prep 
Kit for Illumina (New England BioLabs, Ipswich, 
MA) according to the manufacturer’s protocol. 50 
base pair sequencing was performed on the HiSeq 
2500 (Illumina, San Diego, CA). See supporting 
Materials and Methods for details on how data anal-
ysis was performed.
StatIStICS
All graphical values are shown as mean ± stan-
dard error. Statistical analyses were performed using 
GraphPad Prism 8 and the R statistical environment. 
Ordinary one- way ANOVAs with Dunnett’s multiple 
comparisons tests or two- way ANOVAs with Turkey’s 
multiple comparisons tests were performed to test sta-
tistical significance between means. P- values less than 
0.05 were considered statistically significant.
Results
KNoCKoUt oF pNpla3 
DoeS Not aFFeCt HepatIC 
DIFFeReNtIatIoN IN VITRO
To further understand the function of PNPLA3 in 
NAFLD pathogenesis, we decided to take advantage 
of HLCs generated from hiPSCs. This method has 
been used previously to model a diversity of liver dis-
eases in vitro.(18,19) To examine the effect of PNPLA3 
genotype on hepatocyte metabolism, we chose to use 
CRISPR/CAS9 to either knock out PNPLA3 or 
knock in the I148M variant in two wild- type hiPSC 
lines with high capacity for hepatocyte differentiation 
(FSPS13B(15) and A1ATDR/R(16)). This approach 
allowed for the robust phenotypic comparison of 
isogenic hiPSC lines while avoiding variability in 
capacity of differentiation.(20) In sum, off- target opti-
mized sgRNAs targeting exon 3 and ssODN (Fig. 1A 
FIg. 1. Editing PNPLA3 does not affect hepatic differentiation capacity. (A) CRISPR/CAS9 targeting strategy at exon 3 of the 
PNPLA3 gene locus and resulting sequences for the PNPLA3I148M and PNPLA3KO clones used in further experiments. (B) PNPLA3 
mRNA expression in HLCs of each genotype at the exon- exon junctions of exons 2 and 3 as well as exons 3 and 4 (PNPLA3UC, n = 2 
clones and 5 independent experiments; PNPLA3I148M, n = 2 clones and 4 independent experiments; PNPLA3KO, n = 3 clones and 3 
independent experiments) compared with the expression in PHHs (n = 7) and HL samples (n = 3). Ordinary one- way ANOVA with 
Dunnett’s multiple comparisons tests were performed to test statistical significance between means. Data are represented as mean ± SEM. 
PNPLA3UC cells express high levels of PNPLA3 mRNA, comparable to the expression of PNPLA3 in PHH and HL. PNPLA3KO cells 
expressed near zero levels of PNPLA3 mRNA. PNPLA3I148M cells expressed high mRNA levels, though slightly lower than those of the 
PNPLA3UC cells. (C) Protein expression of PNPLA3 following differentiation to HLCs. Expectedly, PNPLA3UC and PNPLA3I148M 
cells expressed high levels of PNPLA3 protein, while PNPLA3KO cells did not express any detectable levels of PNPLA3 protein. These 
results indicate that a full knockout of PNPLA3 was achieved in these cells. (D) mRNA expression of hepatocyte functionality markers 
ALB, HNF4a, and A1AT following hepatocyte differentiation compared with undifferentiated hiPSCs, PHHs, and HLs (PNPLA3UC, 
n = 2 clones and 4 independent experiments; PNPLA3I148M, n = 2 clones and 3 independent experiments; PNPLA3KO, n = 3 clones and 
3 independent experiments; and PHH, n = 7; HL: n = 3). Ordinary one- way ANOVAs with Dunnett’s multiple comparisons tests were 
performed to test statistical significance between means. Data are represented as mean ± SEM. Expression of the three hepatocyte markers 
is up- regulated from hiPSCs to HLCs, and the expression levels of each gene in the HLCs is similar to or higher than the expression level 
in PHH and HL, indicating a successful differentiation toward the hepatocyte lineage. Levels of mRNA expression for each marker are 
similar among the three genotypes, indicating that all genotypes possess a similar capacity to differentiate into HLCs. (E) Basal CYP3A4 
activity in HLCs of each genotype was not statistically different, indicating that all genotypes differentiate into HLCs with similar 
functionality and metabolic activity (PNPLA3UC, n = 2 clones and 11 independent experiments; PNPLA3I148M, n = 2 clones and 15 
independent experiments; and PNPLA3KO, n = 3 clones and 15 independent experiments). Ordinary one- way ANOVA with Dunnett’s 
multiple comparisons tests were performed to test statistical significance between means. Data are represented as mean  ±  SEM. (F) 
Representative images of ALB and HNF4a protein staining in differentiated cells shows similar expression of mature hepatocyte markers 
among all three genotypes. See also Supporting Figs. S1- S3.
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and Supporting Table S2) containing the I148M vari-
ant were nucleofected into hiPSCs, and targeted cells 
were selected using puromycin. Following genotyping 
and sequencing (Fig. 1A and Supporting Figs. S1- 
S3), seven FSPS13B sublines (two untargeted con-
trol [PNPLA3UC], two variant [PNPLA3I148M], and 
three KO [PNPLA3KO]) and five A1ATDR/R sub-
lines (two PNPLA3UC, one PNPLA3I148M, and two 
PNPLA3KO) were chosen for further characterization. 
Of note, PNPLA3UC lines underwent CRISPR/Cas9 
targeting and subcloning but their genetic sequence 
remained unchanged.
The selected cell lines were then differenti-
ated into HLCs using our established protocol(17) 
to characterize the expression of PNPLA3 at both 
the mRNA and protein level (Fig. 1B,C). HLCs 
derived from PNPLA3UC hiPSCs expressed similar, 
if not higher, levels of PNPLA3 mRNA when com-
pared with primary human hepatocytes (PHHs) and 
whole human liver (HL) samples. This high level of 
PNPLA3 expression was confirmed at the protein 
level by immunostaining, thereby confirming the util-
ity of these cells to study PNPLA3 function. On the 
other hand, PNPLA3KO HLCs display extremely low 
level of PNPLA3 mRNA and undetectable levels of 
PNPLA3 protein. Notably, PNPLA3I148M HLCs 
have slightly lower mRNA levels than PNPLA3UC 
HLCs; however, the expression of PNPLA3 mRNA 
in PNPLA3I148M HLCs is similar to that of PHHs. 
Despite the lower mRNA expression in these cells, 
we found similar levels of PNPLA3 protein in 
PNPLA3I148M and PNPLA3UC HLCs. Of note, we 
assessed the effect of insulin and free fatty acid sup-
plementation, two potential inducers of PNPLA3, on 
the expression of PNPLA3 mRNA(21) and found that 
expression is not significantly altered by either treat-
ment (Supporting Fig. S4).
We then decided to further characterize HLCs to 
confirm that changes in PNPLA3 expression and/
or CRISPR/CAS9 gene editing did not affect their 
differentiation and/or function. Gene- expression 
analyses showed that several key hepatocyte markers 
including albumin (ALB), hepatocyte nuclear fac-
tor 4a (HNF4a), and alpha- 1- anti- trypsin (A1AT) 
maintained similar expression across all genotypes 
following differentiation (Fig. 1D). The expression 
of these markers was similar (ALB and HNF4a) or 
higher (A1AT) in our HLCs compared with PHHs 
and HLs, indicating that these cells are comparable to 
primary human samples. Additionally, CYP3A4 activ-
ities were comparable among all three genotypes (Fig. 
1E), while protein expression of functional hepatocyte 
markers (ALB and HNF4a) was again similar among 
the three genotypes (Fig. 1F). Characterization of 
the A1ATDR/R sublines showed similar results 
(Supporting Fig. S2). Taken together, these data indi-
cate that all selected hiPSC sublines, regardless of 
PNPLA3 genotype, can differentiate into HLCs.
pNpla3 Ko aND tHe I148M 
VaRIaNt pRoteCt HlCS 
agaINSt Fatty aCID– INDUCeD 
StReSS
NAFLD is a complex metabolic disorder that is 
characterized, in part, by an increased flux of free 
fatty acids (FFAs) into the liver.(22) After entering 
the hepatocytes, FFAs can either be stored as meta-
bolically inert triglycerides (TGs) in lipid droplets or 
metabolized for energy through a variety of pathways 
including β- oxidation. Overactivity of the β- oxidation 
pathway can result in the buildup of toxic metabolites 
and activation of the unfolded protein response, which 
leads to lipotoxicity.(23) Thus, we decided to analyze 
the effects of PNPLA3 mutations on steatosis and 
lipid- induced stress by treating HLCs with OA or 
PA, respectively. Following a 1- week treatment, lipid 
accumulation was measured using immunofluores-
cence or flow cytometry (Fig. 2). In all three treatment 
groups (control, OA, and PA), PNPLA3UC HLCs 
accumulated the fewest lipid droplets, PNPLA3KO 
cells accumulated the most lipid droplets, and the 
PNPLA3I148M cells exhibited an intermediate phe-
notype between the two. These differences were most 
profound in the PA- treated group, in which only 40% 
of PNPLA3UC cells accumulated lipid droplets, while, 
unexpectedly, PNPLA3KO cells were highly steatotic 
with over 80% of cells accumulating lipid droplets.
Next, we measured the viability of the cells following 
PA treatment (Fig. 3A). As expected in PNPLA3UC 
HLCs, OA treatment had minimal effect, whereas PA 
treatment resulted in profound loss of viability. On the 
other hand, PNPLA3KO HLCs were far less sensitive to 
the PA- induced lipotoxicity and maintained high viabil-
ity close to 80% when compared with untreated cells. The 
PNPLA3I148M variant showed an intermediate pheno-
type. Additionally, we assessed the expression of endo-
plasmic reticulum (ER) stress markers. After 48 hours 
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of PA treatment, PNPLA3UC cells up- regulated the cell 
stress markers binding immunoglobulin protein (BIP), 
growth arrest and DNA damage inducible protein 
(GADD34), C/EBP homologous protein (CHOP), 
and protein kinase R- like endoplasmic reticulum kinase 
(PERK) (Fig. 3B). The expression of these markers was 
significantly lower in PNPLA3KO cells. Finally, we ana-
lyzed the mRNA expression and activation of CASP1 
following 1 week of treatment (Fig. 3C,D). PNPLA3- 
edited HLCs failed to up- regulate CASP1 expression 
and activation in response to PA, indicating that these 
cells have an altered reaction to lipid- induced stress. We 
confirmed the major phenotypic findings in the second 
genetic background (Supporting Fig. S5). To confirm 
that PNPLA3- edited cells are resistant to saturated 
fatty acid (SFA)– induced stress, we performed similar 
experiments using SA. SA was slightly more steatogenic 
and slightly less lipotoxic, but generally we observed 
similar lipid accumulation, viability, and ER stress phe-
notypes as PA treatment (Supporting Fig. S6).
FIg. 2. PNPLA3- edited HLCs accumulate more lipid droplets than PNPLA3UC HLCs. Cells were differentiated into HLCs, placed 
in 3D, and treated for 1 week with control, OA, or PA medium. Flow cytometric analyses were done using 2D cells. (A) Representative 
images of BODIPY- stained lipid droplets in cells from the three genotypes. Regardless of treatment type, progressively more lipids were 
accumulated in PNPLA3I148M cells and PNPLA3KO cells than PNPLA3UC cells. (B) Quantification of the BODIPY staining intensity 
relative to cell number in (A) (PNPLA3UC, n = 6 images per clone, 2 clones, and 2 independent experiments; PNPLA3I148M, n = 6 images 
per clone, 2 clones, and 2 independent experiments; PNPLA3KO, n = 6 images per clone, 2 clones, and 2 independent experiments). A two- 
way ANOVA with Tukey’s multiple comparisons tests was performed to test statistical significance between means. Data are represented 
as mean ± SEM. (C) Representative flow cytometric analysis of lipid accumulation through BODIPY staining. (D) Quantification of the 
percentage of BODIPY- positive cells in (C) (PNPLA3UC, n = 2 clones and 5 independent experiments; PNPLA3I148M, n = 2 clones and 
5 independent experiments; and PNPLA3KO, n = 3 clones and 2 independent experiments). A two- way ANOVA with Tukey’s multiple 
comparisons tests was performed to test statistical significance between means. Data are represented as mean ± SEM. There was a stepwise 
increase in lipid accumulation from PNPLA3UC to PNPLA3I148M to PNPLA3KO cells. This increase in steatosis in the PNPLA3- edited 
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We also treated HLCs for 24 and 48  hours to 
determine how quickly the differences in lipid accu-
mulation develop (Supporting Fig. S7). We found 
that the lipid accumulation phenotypes of the three 
genotypes were apparent even at the earliest time-
point. However, 1  week of PA treatment was neces-
sary to produce lipotoxicity in PNPLA3UC cells. This 
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chronic disease that takes years or decades to develop. 
Therefore, it is possible that prolonged exposure to 
maladaptive lipids is necessary to cause sufficient cel-
lular stress to induce toxicity.
To determine the underlying mechanism driving 
the increased lipid accumulation in PNPLA3- edited 
cells, we chose to examine the expression of markers 
of the three major lipid- processing pathways: de novo 
lipogenesis (DNL), VLDL secretion, and β- oxida-
tion (Supporting Fig. S8). We found no major differ-
ences between genotypes in the expression of DNL 
or VLDL secretion genes. However, PNPLA3- edited 
cells expressed significantly lower levels of several 
β- oxidation genes. This indicates that despite the 
higher abundance of lipids in PNPLA3- edited HLCs, 
these cells failed to up- regulate lipid metabolism path-
ways to catabolize and eliminate excess lipids.
pNpla3 loSS oF FUNCtIoN 
ReSUltS IN aN INCReaSeD 
pRoDUCtIoN oF tgS
Recent literature demonstrates an increasing 
appreciation for lipids as more than just metabolic 
byproducts.(24) Indeed, lipids often serve as signaling 
molecules, and lipidomic signatures can be used to 
differentiate between healthy and diseased individuals. 
Accordingly, carriers of the PNPLA3 I148M variant 
have a unique lipidomic signature that differentiates 
them from both healthy individuals and those with 
obesity- induced NAFLD.(25,26) To assess the effect of 
PNPLA3 genotype on lipid metabolism in our sys-
tem, we performed lipidomic profiling. These analyses 
confirmed that FFA treatment alters the lipid signa-
ture, and more importantly that the PNPLA3 geno-
type had a major effect on HLCs’ lipidomic profile. 
Principle component analysis (PCA) plots comparing 
PNPLA3KO and PNPLA3UC groups showed a com-
plete separation among the genotypes regardless of 
treatment (Fig. 4A,C- E). An intermediate phenotype 
between the PNPLA3UC and PNPLA3KO HLCs was 
observed with PNPLA3I148M cells (Supporting Fig. 
S10). Heatmaps of the top 25 differentially abundant 
lipid species indicated that TGs were the species most 
responsible for these differences (Fig. 3B- E).
Lipidomic profiles revealed that PNPLA3KO HLCs 
had generally higher levels of TGs (Fig. 3F). Of note, 
PNPLA3- edited HLCs preferentially accumulated 
TGs containing four to nine double bonds regardless of 
lipid treatment. These data are consistent with previous 
findings that the I148M variant causes a reduction in 
lipid droplet remodeling capacity and results in hepatic 
retention of polyunsaturated fatty acids (PUFAs).(26) 
This pattern of PUFA accumulation in hepatic TG 
may have profound effects on lipid metabolism: PUFAs 
inhibit sterol regulatory element binding protein 1c, 
causing the down- regulation of DNL, which is charac-
teristic of patients with the I148M variant. This reduc-
tion in DNL may prevent the accumulation of toxic 
intermediates that contribute to lipotoxicity and insulin 
FIg. 3. PNPLA3- edited cells are resistant to PA- induced lipotoxicity. Cells were differentiated into HLCs, placed in 3D, and treated 
for 48 hours to 1 week with control, OA, or PA medium to assess the effect of fatty acid treatment on the viability of HLCs. (A) 
Relative viability of FFA- treated cells to control cells within each genotype (PNPLA3UC, n = 2 clones and 3 independent experiments; 
PNPLA3I148M, n = 2 clones and 7 independent experiments; and PNPLA3KO, n = 3 clones and 5 independent experiments). Ordinary 
one- way ANOVA with Dunnett’s multiple comparisons tests were performed to test statistical significance between means. Data are 
represented as mean ± SEM. PNPLA3UC cells are susceptible to PA lipotoxicity, while PNPLA3KO cells are resistant to this lipotoxic 
insult. PNPLA3I148M cells show an intermediate phenotype between them. (B) mRNA expression of ER stress markers BIP, GADD34, 
CHOP, and PERK following 48 hours of FFA treatment (PNPLA3UC, n = 2 clones and 2 independent experiments; PNPLA3I148M, 
n = 2 clones and 2 independent experiments; and PNPLA3KO, n = 3 clones and 2 independent experiments). Two- way ANOVAs with 
Tukey’s multiple comparisons tests were performed to test statistical significance between means. Data are represented as mean ± SEM. 
In PNPLA3UC cells, ER stress markers are induced by PA treatment. PNPLA3I148M and PNPA3KO cells are resistant the induction of 
ER stress markers following PA treatment. (C) mRNA expression of CASP1 following 1 week of FFA treatment (PNPLA3UC, n = 2 
clones and 6 independent experiments; PNPLA3I148M, n = 2 clones and 6 independent experiments; and PNPLA3KO, n = 3 clones and 
6 independent experiments). Two- way ANOVAs with Tukey’s multiple comparisons tests were performed to test statistical significance 
between means. Data are represented as mean ± SEM. (D) Caspase 1 activity in HLCs treated with FFAs for 1 week (PNPLA3UC, n = 2 
clones and 1 independent experiment; PNPLA3I148M, n = 2 clones and 1 independent experiment; and PNPLA3KO, n = 2 clones and 
1 independent experiment). Two- way ANOVAs with Tukey’s multiple comparisons tests were performed to test statistical significance 
between means. Data are represented as mean ± SEM. Treatment with PA induces the expression of CASP1 in PNPLA3UC cells, indicating 
that the PA- induced lipotoxicity is mediated through inflammasome activation and pyroptosis. PNPLA3- edited cells fail to up- regulate 
CASP1 expression in response to PA treatment. See also Supporting Figs. S5 and S6. Abbreviations: GADD34, growth arrest and DNA 
damage inducible protein; PERK, protein kinase R- like endoplasmic reticulum kinase.
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FIg. 4. Lipidomic comparison of PNPLA3UC and PNPLA3KO following FFA treatment. Lipidomic differences between PNPLA3UC 
and PNPLA3KO cells treated with control, OA, and PA media for 1 week were analyzed (PNPLA3UC, n = 2 clones [with 5 technical 
replicates] and 1 independent experiment; PNPLA3KO, n = 3 clones [with 5 technical replicates] and 1 independent experiment). (A) 
Projection to latent structure discriminant analysis plot of the six experimental groups. The two genotypes cluster separately, with slight 
differences attributable to the FFA treatment within each genotype. (B) Heatmap of the top 25 differentially abundant lipid species in all 
six experimental groups. The lipid species most responsible for lipidomic differences between groups is TGs. PCA plot and heatmap of the 
top 25 differentially abundant lipid species comparing the effect of control medium (C), OA medium (D), and PA medium (E) on genotypic 
differences. Regardless of treatment, PNPLA3UC and PNPLA3KO cells clustered far apart from one another. Once again, TGs were a major 
determinant in driving lipidomic differences among the groups. (F) Heatmaps showing the log2- fold change difference in abundance of 
TGs that were statistically differentially abundant between PNPLA3UC and PNPLA3KO cells following the three treatments. In the PA 
treatment group, this analysis indicates that PNPLA3KO cells may be preferentially incorporating SFAs into TGs, as a plurality of TGs that 
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resistance. Therefore, the preferential accumulation of 
PUFA- containing TG species may be cytoprotective 
against the ER stress caused by lipid overload in these 
cells. Additionally, the TG profile of PA- treated cells 
revealed that PNPLA3KO HLCs incorporated more 
SFAs into TGs than PNPLA3UC HLCs (Fig. 4F and 
Supporting Fig. S10F). In support of the hypothesis 
that PNPLA3 is a major lipid droplet remodeling pro-
tein, we found that PNPLA3- edited HLCs significantly 
down- regulate the expression of several lipid droplet 
markers (Supporting Fig. S8). Thus, loss of PNPLA3 
functionality could result in dysregulated lipid droplet 
remodeling, which causes alterations to the lipid pool as 
well as the protein coating of lipid droplets.
To contextualize our model in terms of the 
human disease, we compared the lipidomic profile 
of PNPLA3I148M cells with published data of both 
the circulating(25) and hepatic lipidomic profiles(26) of 
homozygous PNPLA3 I148M carriers (Fig. 5). Given 
that TGs were the lipid species with the largest differ-
ence in the lipidomic profile of our cells, we confined 
our analysis to TGs. We found that of the 20 TG 
species that were up- regulated in I148M carriers, 12 
were similarly up- regulated in the PNPLA3I148M cells. 
This analysis indicated that PNPLA3I148M cells closely 
resemble the lipidomic profile of liver biopsies from 
I148M carriers. Of the 12 TGs that were up- regulated 
in PNPLA3I148M HLCs, 10 were exclusively found in 
the lipidomic samples from patient liver biopsies. The 
TG species that were common between our system and 
the patients were all PUFAs. This result offers clinical 
validation of our system, as we were able to recapitu-
late major aspects of the PNPLA3- induced NAFLD 
phenotype in humans. To conclude, loss of function of 
PNPLA3 results in major modification in lipidomic 
profile of HLCs, suggesting an improved transforma-
tion of FFAs into TGs as well as reduced lipid droplet 
remodeling capacity.
tRaNSCRIptoMIC aNalySeS 
ReVeal tHat loSS oF FUNCtIoN 
IN pNpla3 BRoaDly aFFeCtS 
lIpID MetaBolISM IN HlCS
To further uncover the molecular mechanisms 
involved in the PNPLA3 phenotype, we performed 
RNA- sequencing (RNA- Seq) analyses on HLCs 
grown in the presence of FFAs. The resulting data 
FIg. 5. PNPLA3I148M cells mirror lipidomic profile of liver biopsies from homozygous PNPLA3 I148M carriers. Table shows up- 
regulated TG species of PNPLA3 I148M carriers in circulating samples (Hyysalo et al.) and liver biopsies (Luukkonen et al.) compared 
with PNPLA3I148M lipidomic samples. The PNPLA3I148M lipidomic profile more closely resembles the profile of liver biopsies from 
patients with PNPLA3 I148M than the circulating lipidomic profile. The significant overlap (12 of 17 species) between our system and 
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sets were analyzed using PCA and showed that 
regardless of treatment, PNPLA3UC HLCs displayed 
a different transcriptomic profile when compared 
with PNPLA3KO cells, while PNPLA3I148M cells 
appeared to have an intermediate profile (Fig.  6A). 
This observation was further confirmed by heat-
map analyses of the top 500 differentially expressed 
genes between PNPLA3KO and PNPLA3UC HLCs 
in each treatment (Fig. 6B and Supporting Table S5). 
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fundamentally alters the transcriptomic profile of 
HLCs, while lipid treatment merely exacerbates the 
underlying phenotype. This finding is consistent 
with our findings showing that PNPLA3- edited cells 
demonstrated increased lipid accumulation and altered 
lipidomic profiles at baseline.
The top 500 differentially expressed genes between 
PNPLA3UC and PNPLA3KO in each treatment 
group were then subjected to Gene Ontology path-
way analysis (Fig. 6C), which highlighted a profound 
down- regulation of several metabolic pathways in the 
PNPLA3KO cells. After closer inspection, we found 
that in addition to lipid metabolism, PNPLA3KO 
HLCs down- regulated genes responsible for glucose 
metabolism, xenobiotic metabolism, and cell stress 
(Fig. 6D). Interestingly, insulin receptor signaling 
appeared to be up- regulated, which could explain a 
decrease in genes involved in glycogenolysis and glu-
coneogenesis (PCK1, PC, and G6PC). This finding 
indicated that PNPLA3KO cells may maintain insu-
lin sensitivity in spite of steatosis, which is consistent 
with the clinical characteristics of I148M carriers. 
Additionally, the expression of several lipid droplet– 
remodeling proteins was altered in PNPLA3KO cells. 
The fatty acid desaturase 6 (FADS6) gene, which 
is responsible for desaturating fatty acids, was up- 
regulated, while the lipolytic enzymes LIPC and 
LIPG were down- regulated. This expression pat-
tern supports the hypothesis that PNPLA3 is a lipid 
droplet– remodeling protein, and loss of this function 
fundamentally alters lipid droplet dynamics.
In addition to lipid and glucose metabolism, 
PNPLA3KO HLCs also down- regulated genes 
responsible for all three phases of drug metabo-
lism. These genes included, but were not limited to, 
the CYP, UGT, and SLC families of enzymes. In 
accordance with our finding that PNPLA3KO cells 
are resistant to PA- induced lipotoxicity, we found that 
these cells tended to exhibit lower expression of sev-
eral key cell stress markers including UCP2, SOD3, 
BIP, and CHOP.
PCA of the RNA- Seq data among the genotypes 
in response to FFA (Supporting Fig. S11) showed that 
PA treatment had the strongest effect on the gene- 
expression profile of PNPLA3UC HLCs. Interestingly, 
both PNPLA3I148M and PNPLA3KO HLCs did not 
cluster separately based on treatment type. Taken 
together, these data show that absence of PNPLA3 or 
the presence of the Il48M variant profoundly changes 
the gene expression of HLCs, which in turn alters 
their capacity to react against lipid stressors. Thus, the 
transcriptomic similarities between PNPLA3 geno-
types reinforce our observation that the Il48M variant 
represents a loss of function.
Of note, the transcriptomic profile of our PNPLA3- 
edited HLCs also mimicked that of patients carrying 
the I148M variant. In a study analyzing the transcrip-
tomic differences between carriers and noncarriers of 
the I148M variant, Baselli et al. found that carriers 
down- regulated oxidative phosphorylation, fatty acid 
metabolism, and xenobiotic metabolism.(27) These 
data offer further clinical validation of our hypotheses 
that the I148M variant disrupts cellular metabolism 
on a global scale, leading to reduced lipid and xenobi-
otic metabolism.
BloCKINg tg FoRMatIoN 
ReSeNSItIZeS pNpla3Ko CellS 
to pa- INDUCeD toXICIty
Based on these results, we hypothesized that the 
reduced β- oxidation and increased incorporation of 
FIg. 6. The intermediate phenotype of PNPLA3I148M indicates that the variant may be loss of function. Transcriptomic differences among 
PNPLA3UC, PNPLA3I148M, and PNPLA3KO cells treated with control, OA, and PA media for 24 hours were analyzed (PNPLA3UC, n = 2 
clones and 2 independent experiments; PNPLA3I148M, n = 1 clones and 2 independent experiments; and PNPLA3KO, n = 2 clones and 
2 independent experiments). (A) PCA plots comparing the three genotypes following the respective treatments. Regardless of treatment, 
PNPLA3UC and PNPLA3KO cells clustered far apart from one another, whereas PNPLA3I148M cells are positioned between the two, 
indicating that it represents an intermediate phenotype. (B) Heatmaps of the top 500 differentially expressed genes between PNPLA3UC 
and PNPLA3KO cells for each treatment. This once again shows that PNPLA3I148M cells have a transcriptomic expression profile that is 
intermediate between those of PNPLA3UC cells and PNPLA3KO cells. (C) Gene ontology enrichment analysis comparing PNPLA3UC 
and PNPLA3KO cells. Statistically significantly up- regulated pathways are shown in green, and down- regulated pathways are shown in red. 
Metabolic processes are highlighted with a star. These results indicate that PNPLA3KO cells down- regulate several metabolic pathways 
compared with PNPLA3UC cells, regardless of treatment type. (D) Log2- fold change expression of selected differentially expressed genes 
in PNPLA3KO cells compared with PNPLA3UC cells. Lipid and glucose metabolism genes are shown in black; xenobiotic metabolism 
genes are shown in gray; and cell stress genes are shown in white. Generally, PNPLA3KO cells down- regulate genes involved in each of the 
these pathways compared with PNPLA3UC cells, regardless of treatment type. See also Supporting Fig. S11.
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harmful SFAs into TGs could represent the mech-
anism by which PNPLA3KO HLCs reduce SFA- 
induced lipotoxicity. Accordingly, it has been shown 
previously that shuttling SFAs into TGs instead of 
other metabolic processes results in decreased lipotox-
icity.(28) To test this hypothesis, we blocked TG syn-
thesis in HLCs treated with PA using small molecule 
inhibitors. Because it is unknown where in the TG 
enzyme cascade PNPLA3 might act, two inhibitors 
were chosen: triacsin C to block GPAT at the top of 
the enzyme cascade, and T863 to block DGAT at the 
bottom of the cascade. Both triacsin C and T863 sig-
nificantly reduced lipid droplet accumulation in HLCs 
treated with either OA (Supporting Fig. S12) or PA 
(Fig. 7A,B). Viability of HLCs treated with PA + 
DMSO, PA + triacsin C, and PA + T863 was then 
assessed (Fig. 7C). In PNPLA3UC HLCs, the addition 
of the inhibitors had no effect on cell death induced by 
PA treatment. On the other hand, addition of triacsin C 
and T863 resulted in a statistically significant reduction 
in viability in PNPLA3KO HLCs grown in the pres-
ence of PA. Once again, PNPLA3I148M HLCs showed 
an intermediate phenotype between PNPLA3UC and 
PNPLA3KO cells. These findings were confirmed in 
a second genetic background (Supporting Fig. S11). 
Together, these results indicate that blocking TG for-
mation could, in part, resensitize PNPLA3KO cells to 
PA- induced toxicity. However, given that the increased 
toxicity by blocking TG formation was not observed 
in PNPLA3UC cells when treated with PA, addi-
tional mechanisms may contribute to the resistance of 
PNPLA3KO cells to lipid- induced stress.
loSS oF pNpla3 FUNCtIoN 
ReSUltS IN INCReaSeD 
SUSCeptIBIlIty to etHaNol 
toXICIty
To explore the mechanism of PNPLA3KO and 
PNPLA3I148M genotypes in liver injury in addition 
to steatosis, we hypothesized that the increased lipid 
loading in these cells along with their altered lipid 
and xenobiotic metabolism would make them more 
susceptible to other forms of toxicity. We chose to 
test this hypothesis using ethanol and methotrex-
ate, whose hepatotoxic effects may be modulated by 
PNPLA3 genotype.(29,30) Descriptions of the treat-
ment timeline can be found in Fig. 8A,C. PNPLA3KO 
HLCs were significantly less viable than PNPLA3UC 
cells after ethanol/TNF or methotrexate treatment, 
whereas PNPLA3I148M cells displayed an intermedi-
ate sensitivity (Fig. 8B,D). Even though the concen-
trations of both hepatotoxins were relatively nontoxic 
to PNPLA3UC cells, they induced a high level of cell 
death in PNPLA3KO HLCs. The increased suscep-
tibility of PNPLA3- edited cells to ethanol- induced 
hepatotoxicity was confirmed in the second genetic 
background (Supporting Fig. S13). The increased 
toxicity is likely driven by the lower expression of 
drug metabolizing enzymes that play a role in detox-
ification of these hepatotoxins (Fig. 8E). Ethanol 
toxicity has been shown to be dependent on the acti-
vation of stress kinases, including p- JNK and pp38- 
MAPK.(31,32) The expression of these two kinases 
was highly induced in PNPLA3KO HLCs following 
ethanol and TNF treatment, while the PNPLA3UC 
HLCs were relatively resistant to this induction, mir-
roring the genotypes’ susceptibility to toxicity (Fig. 
8F,G). Importantly, PNPLA3KO HLCs expressed a 
higher basal level of both kinases, which may explain 
their increased susceptibility to hepatotoxicity. These 
findings suggest that changes in PNPLA3 activity 
increase susceptibility to hepatotoxic agents, thereby 
explaining the contribution of the Il48M variant to 
the progression of the disease toward NASH.
Discussion
Using our hiPSCs model system, we demonstrated 
that changes in PNPLA3 activity have major effects 
on the metabolic activity of human hepatocytes, which 
may in turn influence the progression of NAFLD. 
This study report in a human hepatic system that the 
I148M variant in the PNPLA3 gene leads to NAFLD 
disease progression through a loss of function muta-
tion. Our data indicate that loss of PNPLA3 activity 
leads to increased steatosis and resistance to SFA- 
induced cell stress in vitro. This latter phenotype is 
counter- intuitive, at least in part, due to the down- 
regulation of lipid metabolism that leads to excessive 
diversion of SFAs into TGs. More importantly, loss of 
PNPLA3 leads to the down- regulation of xenobiotic 
metabolism in hepatocytes, making them more sus-
ceptible to other hepatotoxins such as ethanol. Thus, 
subclinical but sustained damage to the livers of these 
patients caused by environmental hepatotoxins may 
result in disease progression to NASH.
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Importantly, previous genetic studies in the mouse 
have shown that absence of PNPLA3 does not result 
in a NAFLD- like phenotype.(12) However, when 
either the I148M PNPLA3 protein or a catalytically 
dead version of PNPLA3 (S47A) are overexpressed 
in mouse livers, these mutant proteins accumulate 
on the surfaces of lipid droplets, which may restrict 
either cofactors or lipid mobility. As a consequence, 
the effect of the I148M variant is often considered a 
gain of function. Accordingly, multiple companies are 
now developing PNPLA3 inhibitors to limit NAFLD 
aggravation based on these observations.(33) However, 
this finding fails to account for the substantial 
sequence divergence of mouse and human PNPLA3 
FIg. 7. Blocking TG formation resensitizes PNPLA3KO cells to PA- induced lipotoxicity. TG formation was blocked using small 
molecule inhibitors triacsin C and T863. (A) Representative images of BODIPY lipid staining following 1 week of treatment with PA 
and PA supplemented with the respective inhibitors. (B) Quantification of the BODIPY staining intensity relative to cell number in (A) 
(PNPLA3UC, n = 4 images per clone, 2 clones, and 3 independent experiments; PNPLA3I148M, n = 4 images per clone, 2 clones, and 2 
independent experiments; and PNPLA3KO, n = 4 images per clone, 2 clones, and 2 independent experiments). A two- way ANOVA with 
Tukey’s multiple comparisons tests was performed to test statistical significance between means. Data are represented as mean ± SEM. 
Lipid accumulation was incompletely inhibited by both inhibitors in all three genotypes. (C) Relative viability of PA and PA + inhibitor– 
treated cells to control treated cells within each genotype (PNPLA3UC, n = 2 clones and 3 independent experiments; PNPLA3I148M, 
n = 1 clone and 4 independent experiments; and PNPLA3KO, n = 2 clones and 4 independent experiments). Ordinary one- way ANOVAs 
with Dunnett’s multiple comparisons tests were performed to test the statistical significance between means. Data are represented as 
mean ± SEM. For PNPLA3UC cells, treatment with PA resulted in a significant loss of viability, but treatment with the TG inhibitors 
did not result in additional loss of viability. However, treatment with both inhibitors resulted in a significant reduction in viability for 
PNPLA3KO cells. PNPLA3I148M cells showed an intermediate phenotype with a slight reduction in viability when treated with the TG 
inhibitors that did not reach significance. See also Supporting Fig. S12.
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genes as well as the differences in tissue localization 
of PNPLA3 between these species. Indeed, PNPLA3 
is endogenously expressed at extremely low levels in 
mouse livers and high levels in adipose tissue.(9,13,14) 
Accordingly, it has been shown that PNPLA3 must 
be overexpressed in liver tissue for a phenotype to be 
observed.(34)
Importantly, previous in vitro studies as well as 
some studies in human cohorts have demonstrated 
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activity.(26,35) Of particular interest, Luukkonen et 
al. showed that knocking out PNPLA3 results in 
lipid accumulation in the immortalized skin cell 
line A431.(26) Additionally, Romeo et al. found that 
patients with mutations in the PNPLA3 gene that 
were likely to be null presented with a phenotype 
closely resembling the I148M carriers.
It should be noted that one study did identify that 
the rs2294918 SNP in PNPLA3, which is associated 
with lower expression of PNPLA3, caused a slight 
improvement in NAFLD- associated traits in carri-
ers of the I148M variant. However, this study also 
found that in reducing the expression of the wild- 
type PNPLA3 enzyme, the rs2294918 SNP reduced 
the protective effect of the wild- type allele against 
NAFLD development and progression. This finding 
implies that reduced expression of PNPLA3 protein 
predisposes patients to NAFLD and offers further 
evidence that reduced PNPLA3 expression and/or 
functionality is pathogenic. Although there are pro-
found interspecies differences in the functionality and 
pathogenicity of PNPLA3 between mice and humans, 
some data from murine models do support the 
hypothesis that I148M is a loss of function variant. 
Indeed, overexpression of a catalytically dead version 
of PNPLA3 results in a similar phenotype as over-
expression of the I148M variant,(26,35) indicating that 
the I148M variant is equivalent to loss of PNPLA3 
catalytic function in mouse livers. Taken together, 
these findings support our conclusion that the I148M 
variant is a loss- of- function mutation that leads to 
more severe NAFLD in human.
The I148M variant in PNPLA3 has been shown 
in more than 50 studies to be robustly correlated with 
the full spectrum of NAFLD from simple steato-
sis through NASH, fibrosis, cirrhosis, and HCC.(6) 
However, the molecular mechanism by which this 
variant contributes to NAFLD remains unclear. As 
expected, the I148M variant caused an increase in 
lipid accumulation in our system. This finding is in 
direct agreement with the clinical evidence. However, 
our data also show that the variant is protective against 
saturated SFA- induced cell stress in vitro. Because 
the variant has been linked to worsening disease 
progression, this finding seems contradictory. There 
are several reasonable explanations for this apparent 
discrepancy.
First, SFAs exert their maladaptive effects in vivo by 
exacerbating insulin resistance. Selective insulin resis-
tance leading to oxidative stress, mitochondrial dys-
function, and inflammation is a hallmark of NAFLD 
caused by metabolic disease.(36- 38) Conversely, carri-
ers of the I148M variant have lower levels of DNL 
and maintain insulin sensitivity despite high- grade 
FIg. 8. Loss of PNPLA3 function results in increased susceptibility to ethanol and methotrexate toxicity. (A) Timeline of ethanol 
+ TNFa treatment to induce toxicity. (B) Relative viability of ethanol + TNFa– treated cells to untreated cells within each genotype 
(PNPLA3UC, n = 2 clones and 2 independent experiments; PNPLA3I148M, n = 2 clones and 2 independent experiments; and PNPLA3KO, 
n  =  2 clones and 2 independent experiments). A two- way ANOVA with Tukey’s multiple comparisons tests was performed to test 
statistical significance between means. Data are represented as mean ± SEM. Given the sublethal does of ethanol given, PNPLA3UC cells 
retained high viability following treatment. Conversely, PNPLA3KO cells showed an acute toxicity when treated with even a sublethal 
dose of ethanol. PNPLA3I148M cells were intermediate between PNPLA3UC and PNPLA3KO cells. This trend was consistent in both 
control and OA- treated cells, indicating that this effect may be independent of steatosis. (C) Timeline of methotrexate treatment to 
induce toxicity. (D) Relative viability of methotrexate treated cells to untreated cells within each genotype (PNPLA3UC, n = 2 clones 
and 6 independent experiments; PNPLA3I148M, n  =  2 clones and 3 independent experiments; and PNPLA3KO, n  =  2 clones and 4 
independent experiments). A two- way ANOVA with Tukey’s multiple comparisons tests was performed to test statistical significance 
between means. Data are represented as mean ± SEM. (E) mRNA expression of the drug metabolizing enzymes ADH1A, ALDH2, 
UGT1A1, and UGT2B4 among the three genotypes (PNPLA3UC, n = 2 clones and 2 independent experiments; PNPLA3I148M, n = 2 
clones and 2 independent experiments; and PNPLA3KO, n = 2 clones and 2 independent experiments). Ordinary one- way ANOVAs with 
Dunnett’s multiple comparisons tests were performed to test statistical significance between means. Data are represented as mean ± SEM. 
PNPLA3- edited cells express significantly lower levels of these drug- metabolizing enzymes that are relevant for ethanol and methotrexate 
metabolism. The lower expression of these drug metabolizing enzymes may contribute to the increased toxicity burden in these genotypes. 
(F) Representative western blot and quantification graph showing protein expression of pp38- MAPK in the three genotypes with (+) and 
without (- ) treatment with ethanol and TNF (PNPLA3UC, n = 1 clone and 2 independent experiments; PNPLA3I148M, n = 2 clones and 
2 independent experiments; and PNPLA3KO, n = 2 clones and 2 independent experiments). This experiment was performed using the 
protein simple whole- exome sequencing machine. (G) representative western blot and quantification graph showing protein expression 
of p- JNK in the three genotypes with (+) and without (- ) treatment with ethanol and TNF (PNPLA3UC, n = 1 clone and 2 independent 
experiments; PNPLA3I148M, n = 2 clones and 2 independent experiments; and PNPLA3KO, n = 2 clones and 2 independent experiments). 
This experiment was performed using standard western blotting techniques. See also Supporting Fig. S13.
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steatosis and liver injury.(4,25,39,40) Therefore, the resis-
tance of PNPLA3- edited HLCs to SFA- induced cell 
stress may be more indicative of the intact insulin 
signaling pathway rather than true resistance to lipo-
toxic injury— a distinction that is difficult to discern 
in an in vitro system.(23,37) Furthermore, the patho-
genesis of NASH is likely multifactorial and not 
simply explained by a direct lipotoxic effect of SFAs. 
Clinical studies indicate that the NAFLD disease 
profile of I148M carriers is different from that of 
NAFLD caused by obesity and metabolic syndrome. 
Consequently, it is reasonable to hypothesize that 
lipid- induced injury may occur via a mechanism other 
than saturated SFA- induced lipotoxicity and insulin 
resistance in carriers of the I148M variant compared 
to NAFLD patients with metabolic syndrome.
Second, our functional studies show that concom-
itant down- regulation of lipid and xenobiotic metab-
olism pathways causes the PNPLA3- edited cells to 
be more susceptible to other forms of toxicity. This 
model is consistent with the widely accepted con-
cept that environmental factors modulate the effect 
of genetic variants on disease progression of NAFLD. 
Indeed, the I148M variant has been clinically linked 
to several detoxification diseases, including alcohol- 
associated liver disease, hereditary hemochromatosis, 
and drug- induced liver damage.(29,30,41) Thus, we pro-
pose that the I148M variant in PNPLA3 accelerates 
the progression toward NASH by increasing sensitiv-
ity of hepatocytes to common hepatotoxic compounds 
such as alcohol.
Finally, NAFLD is a complex metabolic disease that 
involves intercellular signaling among several hepatic 
cell types as well as extrahepatic tissues. PNPLA3 is 
known to be expressed in several cell types that are 
relevant to NAFLD, including hepatocytes, stellate 
cells, and macrophages.(42) Thus, we cannot exclude 
that PNPLA3 may affect complex cell– cell interac-
tions involved in fibrosis and cirrhosis. Interestingly, 
our system offers the opportunity to dissect the role of 
PNPLA3 pathogenesis on hepatocytes from the other 
hepatic cells. Given the complex nature of this dis-
ease, it is possible that PNPLA3 differentially affects 
several hepatic cell types to manifest different aspects 
of the disease. In vitro studies indicate that PNPLA3 
plays a role in the activation of hepatic stellate cells, 
and the I148M variant causes increased expression 
of proinflammatory and profibrotic markers as well 
as higher proliferation rate and chemotaxis.(10,42- 44) 
Additionally, the I148M variant in PNPLA3 con-
fers increased risk for fibrosis independent of other 
markers of disease severity.(45,46) Therefore, it is pos-
sible that the increased liver injury in I148M carriers 
is due to the proinflammatory and profibrotic pheno-
type of HSCs, whereas the increased steatosis in the 
hepatocytes of these patients is a distinct phenome-
non. Further studies involving coculture of the dif-
ferent cell types mentioned previously could address 
this question. Given the unique properties of hiPSCs, 
the cell lines developed in this study could be used to 
develop such a complex culture system.
In summary, our study offers insight into the func-
tionality of PNPLA3 and its pathophysiology in 
NAFLD. We believe that this in vitro system rep-
resents a platform to elucidate the full pathophysiol-
ogy of the PNPLA3 I148M variant in NAFLD as 
well as drug development, while minimizing the reli-
ance on live animal models. Our findings may have 
major implications for patient management. Indeed, 
decreasing PNPLA3 activity by pharmacological 
means may be a problematic therapeutic approach, as 
it could increase the risk of liver injury, and patients 
carrying the I148M could benefit from lifestyle mod-
ifications excluding alcohol or other hepatotoxins.
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